MedTechDeals
The board of MedTech Achilles Therapeutics is proposing a members’ solvent voluntary liquidation.
The London-headquartered firm, which has an office in Philadelphia and facilities at Stevenage Bioscience Catalyst, sold some of its technology assets to AstraZeneca late last year for $12m.
Achilles, founded in 2016, was developing precision T cell therapies that target clonal neoantigens – protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system.
Should shareholders back the proposals, it is expected that approximately £1.20 to £1.32 per share would be returned to them. At the close of the markets yesterday, the value of each share was around…
